Checkpoint blockade immunotherapies can be extraordinarily effective, but might benefit
only the minority of patients whose tumors are pre-infiltrated by T cells. Here, using lung …

Recent advances in the understating of tumor immunology suggest that cancer
immunotherapy is an effective treatment against various types of cancer. In particular, the …

The clinical success of immune checkpoint inhibitors has highlighted the central role of the
immune system in cancer control. Immune checkpoint inhibitors can reinvigorate anti-cancer …

Checkpoint blockade has formally demonstrated that reactivating anti-tumor immune
responses can regress tumors. However, this only occurs in a fraction of patients …

Immune checkpoint blockade (ICB) is efficacious in many diverse cancer types, but not all
patients respond. It is important to understand the mechanisms driving resistance to these …

Cancer immunotherapy using antibodies that target immune checkpoints has delivered
outstanding results. However, responses only occur in a subset of patients, and it is not fully …

Current immune checkpoint-modulating agents have demonstrated clinical efficacy in
certain tumor types, particularly those with a high burden of tumor-specific neoantigens, high …

Blocking antibodies to the immune checkpoint receptors or their ligands have revolutionized
the treatment of diverse malignancies. Many tumors are recognized by adaptive immunity …

Despite the clinical success of immune checkpoint blockade (ICB), in certain cancer types,
most patients with cancer do not respond well. Furthermore, in patients for whom ICB is …

Immune checkpoint blockade therapy (ICBT), which blocks negative immune-activating
signals and maintains the antitumor response, has elicited a remarkable clinical response in …